Literature DB >> 2439250

Clinical and biochemical effects during treatment of depression with nortriptyline: the role of 10-hydroxynortriptyline.

C Nordin, L Bertilsson, B Siwers.   

Abstract

Plasma concentrations of nortriptyline (NT) and its major metabolite 10-hydroxy-NT (10-OH-NT) were measured in 30 patients with depression, treated with NT for 3 weeks. Nine patients who recovered completely had plasma concentrations of NT and 10-OH-NT ranging from 358 to 728 nmol/L and from 428 to 688 nmol/L, respectively. Of the 21 patients who did not recover completely, only four had plasma concentrations within the window limited by these two plasma concentration ranges. A correlation was found between the degree of amelioration and the plasma concentration of NT (rs = 0.469; P less than 0.01). Lumbar punctures were performed in 26 patients before and after 3 weeks of NT treatment. During treatment there was a 30.9% mean decrease in the noradrenaline metabolite 4-hydroxy-3-methoxyphenylglycol (HMPG) in cerebrospinal fluid (CSF). We could not evaluate the extent to which this decrease was caused by NT or 10-OH-NT, respectively, because both are strong inhibitors of noradrenaline uptake. The ratio between the concentration of NT and 10-OH-NT in CSF correlated to the reduction of HMPG in CSF (r = 0.397; P less than 0.05) and to the amelioration of depression (rs = 0.623; P less than 0.001). This might indicate that NT and 10-OH-NT interact on the noradrenaline system in a nonadditive way. During treatment there was a 15.2% decrease in CSF concentration of the serotonin metabolite 5-hydroxyindoleacetic acid. The reduction was significantly correlated to the CSF concentration of NT but not to that of 10-OH-NT. This is in accordance with the fact that NT is a more potent inhibitor of serotonin uptake than is 10-OH-NT. The dopamine metabolite homovanillic acid in CSF decreased significantly by 10.0%. The biochemical data indicate that noradrenergic, serotoninergic, and dopaminergic systems are affected by NT treatment and that 10-OH-NT might be more selective on noradrenergic neurons than the parent drug.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2439250     DOI: 10.1038/clpt.1987.101

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  Treatment of depression with E-10-hydroxynortriptyline--a pilot study on biochemical effects and pharmacokinetics.

Authors:  C Nordin; L Bertilsson; M L Dahl; B Resul; G Toresson; F Sjöqvist
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Quantitative pharmacogenetics of nortriptyline: a novel approach.

Authors:  E E Kvist; A Al-Shurbaji; M L Dahl; C Nordin; G Alván; L Ståhle
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype.

Authors:  M L Dahl; L Bertilsson; C Nordin
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

Review 4.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 5.  Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline.

Authors:  C Nordin; L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

6.  CSF/plasma ratio of 10-hydroxynortriptyline is influenced by sex and body height.

Authors:  C Nordin
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 7.  Metabolism of tricyclic antidepressants.

Authors:  M V Rudorfer; W Z Potter
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.